New Delhi: In a recent regulatory update, the Central Drugs Standard Control Organisation (CDSCO) has formally approved the withdrawal of COVID-19 treatment indications, originally granted for restricted emergency use, for Baricitinib Tablets 2 mg and 4 mg, following a request from Eli Lilly and Company (India).

The withdrawal specifically affects the emergency-use authorizations that allowed Baricitinib, either alone or in combination with Remdesivir, to treat hospitalized COVID-19 patients requiring supplemental oxygen, invasive or non-invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). These authorizations had been issued in May 2021 and November 2021, respectively.

Despite this change, Baricitinib tablets will continue to be marketed and prescribed for th

See Full Page